These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9485023)

  • 1. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
    Siddik ZH; Mims B; Lozano G; Thai G
    Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
    Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
    Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
    Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
    Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
    Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
    Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
    Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis.
    Allan LA; Fried M
    Oncogene; 1999 Sep; 18(39):5403-12. PubMed ID: 10498894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
    Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
    Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia.
    Denko NC; Green SL; Edwards D; Giaccia AJ
    Exp Cell Res; 2000 Jul; 258(1):82-91. PubMed ID: 10912790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.